Truist Securities Initiates Coverage On PROCEPT BioRobotics with Buy Rating, Announces Price Target of $58
Truist Securities analyst Richard Newitter initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy rating and announces Price Target of $58.